Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function
2013; Wiley; Volume: 43; Issue: 12 Linguagem: Inglês
10.1111/eci.12166
ISSN1365-2362
AutoresMahmut İlker Yılmaz, Alper Sönmez, Mutlu Sağlam, Halıl Yaman, Hilmi Umut Ünal, Mahmut Gök, Hakkı Çetinkaya, Tayfun Eyıleten, Yusuf Oğuz, Sebahattin Sarı, Ali Osman Yıldırım, Abdülgaffar Vural, Juan Jesús Carrero, Luis Miguel Blanco‐Colio,
Tópico(s)Advanced Glycation End Products research
ResumoSoluble TWEAK (sTWEAK) and asymmetric dimethyl arginine (ADMA) concentrations have been associated with endothelial function in patients with chronic kidney disease (CKD). We tested the hypothesis that the improvement in endothelial function observed after renal transplantation is directly linked to the normalization of both sTWEAK and ADMA.One hundred and seventy-five kidney transplant recipients (71% men; 31·6 ± 9·4 years) were studied immediately before and on the 180th day post-transplantation. At each visit, blood samples were taken to assess circulating levels of sTWEAK and ADMA. Brachial artery endothelium-dependent vasodilatation (FMD) assessments were also performed.Renal transplantation was followed by an improvement in FMD. This improvement was paralleled by an increase in sTWEAK and a reduction in ADMA after transplantation (P < 0·001 for all). Cross-sectionally, both molecules associated with FMD before as well as after transplantation (P < 0·001 for all). Longitudinally, the changes observed in sTWEAK (β = 0·26, P < 0·001) and ADMA (β = -0·44, P < 0·001) levels were independently associated with the improvement of FMD (r(2) = 0·30).Renal transplantation is followed by an improvement of FMD that is independently associated with the normalization of both sTWEAK and ADMA concentrations. We identify two surrogate biomarkers of endothelial function with potential as therapeutic targets.
Referência(s)